Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list.

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Ionis Pharmaceuticals Inc (IONS) reports robust revenue growth and strategic advancements, setting the stage for future ...

The opinion is based on positive data from the phase 3 Balance study, which showed a significant reduction of triglycerides ...

SaveHealth reports that high cholesterol affects 1 in 3 Americans, often without symptoms until serious events occur. It is treatable via lifestyle changes and medications.

Sobi® (STO: SOBI) and Ionis Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...

European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months ...

European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months ...

Vascepa (Icosapent ethyl—FDA approved for severe hypertriglyceridemia and cardiovascular risk reduction), Lovaza (Omega-3-acid ethyl esters—FDA approved for severe hypertriglyceridemia and is ...